Loading
companiesCompany
EnGeneIC
EnGeneIC is an Australian biotech that loads bacterially derived nanocells with chemotherapy and steers them to tumours with antibodies; E-EDV-D682 carries a super-cytotoxic payload to EGFR-expressing cancers.
Also called: EnGeneIC Ltd
Overview
EnGeneIC developed the EnGeneIC Dream Vector (EDV), a 400-nanometre bacterially derived minicell that is packed with a drug and coated with a bispecific antibody so it binds a tumour antigen and is taken up by the cancer cell. The EDVs also stimulate innate immunity. E-EDV-D682 targets EGFR and carries the PNU-159682 payload; it is being tested in pancreatic cancer and other advanced solid tumours, in some studies with immunomodulatory EDVs.
Headquarters
Sydney, AU
Scorecard
All companies#438of 1244 companies, score 7
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +2
0 approved, 0 in phase 3, 1 earlier, 1 targets, 1 registry studies. Formula on the scorecards page.
Type
Website
Founded
2001
Phase 2EDV nanocell (bacterial minicell) drug conjugate
E-EDV-D682 is an experimental EDV nanocell (bacterial minicell) drug conjugate from Engeneic Pty in phase 2 trials for pancreatic ductal adenocarcinoma, aimed at EGFR.
drugs
Phase 2EDV nanocell (bacterial minicell) drug conjugate